NO964155D0 - Progesteronantagonister for fremstilling av legemidler til behandling av dysfunksjonelle uterusblödninger - Google Patents

Progesteronantagonister for fremstilling av legemidler til behandling av dysfunksjonelle uterusblödninger

Info

Publication number
NO964155D0
NO964155D0 NO964155A NO964155A NO964155D0 NO 964155 D0 NO964155 D0 NO 964155D0 NO 964155 A NO964155 A NO 964155A NO 964155 A NO964155 A NO 964155A NO 964155 D0 NO964155 D0 NO 964155D0
Authority
NO
Norway
Prior art keywords
drugs
manufacture
uterine bleeding
dysfunctional uterine
progesterone antagonists
Prior art date
Application number
NO964155A
Other languages
English (en)
Other versions
NO964155L (no
Inventor
Kristof Chwalsz
Klaus Stockemann
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO964155L publication Critical patent/NO964155L/no
Publication of NO964155D0 publication Critical patent/NO964155D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO964155A 1995-02-02 1996-10-01 Progesteronantagonister for fremstilling av legemidler til behandling av dysfunksjonelle uterusblödninger NO964155D0 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1995/000394 WO1996023503A1 (de) 1995-02-02 1995-02-02 Progesteronantagonisten für die herstellung von arzneimitteln zur behandlung von dysfunktionellen uterinen blutungen

Publications (2)

Publication Number Publication Date
NO964155L NO964155L (no) 1996-10-01
NO964155D0 true NO964155D0 (no) 1996-10-01

Family

ID=8165951

Family Applications (1)

Application Number Title Priority Date Filing Date
NO964155A NO964155D0 (no) 1995-02-02 1996-10-01 Progesteronantagonister for fremstilling av legemidler til behandling av dysfunksjonelle uterusblödninger

Country Status (20)

Country Link
US (1) US6451780B1 (no)
EP (1) EP0806952B1 (no)
JP (1) JPH10512889A (no)
KR (1) KR100370908B1 (no)
AT (1) ATE235907T1 (no)
AU (1) AU714959B2 (no)
CA (1) CA2186953C (no)
DE (1) DE59510626D1 (no)
DK (1) DK0806952T3 (no)
ES (1) ES2196063T3 (no)
FI (1) FI117850B (no)
HU (1) HU226276B1 (no)
MX (1) MX9603889A (no)
NO (1) NO964155D0 (no)
NZ (1) NZ287024A (no)
PL (1) PL316533A1 (no)
PT (1) PT806952E (no)
SK (1) SK282570B6 (no)
UA (1) UA37259C2 (no)
WO (1) WO1996023503A1 (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001523639A (ja) * 1997-11-14 2001-11-27 アクゾ・ノベル・エヌ・ベー プロゲストゲン−抗プロゲストゲンレジメン
AR025457A1 (es) 1999-08-31 2002-11-27 Schering Ag Mesoprogestinas (moduladores de receptores de progesterona) para el tratamiento y la prevencion de trastornos ginecologicos benignos hormona-dependientes
US8193252B1 (en) * 1999-08-31 2012-06-05 Bayer Pharma AG Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders
US20020176893A1 (en) * 2001-02-02 2002-11-28 Wironen John F. Compositions, implants, methods, and kits for closure of lumen openings, repair of ruptured tissue, and for bulking of tissue
US6685626B2 (en) 2001-02-02 2004-02-03 Regeneration Technologies, Inc. Compositions, devices, methods, and kits for induction of adhesions
US20080182841A1 (en) * 2001-10-29 2008-07-31 Levine Howard L Vaginally administered anti-dysrhythmic agents for treating pelvic pain
US7556150B2 (en) * 2004-06-07 2009-07-07 Duramed Pharmaceuticals, Inc. Dispenser for progestin used for acute and maintenance treatment of DUB
US8173626B2 (en) * 2006-03-08 2012-05-08 Danco Laboratories Llc Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders
HRP20160689T1 (hr) 2007-04-20 2016-07-15 Preglem S.A. Selektivni modulatori progesterona za tretman uterinog krvarenja
US20090118253A1 (en) * 2007-11-05 2009-05-07 Repros Therapeutics Inc. Compositions and methods for treating dysfunctional uterine bleeding
US12011423B2 (en) 2007-11-06 2024-06-18 Foraviset Ltd. S-alkylisothiouronium derivatives for treating uterine hypercontractility disorders
US8299050B2 (en) * 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
TWI477276B (zh) * 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
TWI539953B (zh) * 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
EP2545922A1 (en) * 2011-07-12 2013-01-16 PregLem S.A. Treatment of excessive menstrual bleeding associated with uterine fibroids
EP2854763B1 (en) 2012-05-31 2018-09-26 Repros Therapeutics Inc. Formulations for vaginal delivery of antiprogestins
JP6343619B2 (ja) 2012-11-02 2018-06-13 レプロス セラピューティクス インコーポレイティド プロゲステロン依存性病態を処置する方法およびその組成物
US11110103B2 (en) 2015-12-23 2021-09-07 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
US11208432B2 (en) 2015-12-23 2021-12-28 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
WO2017112902A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
PL3523315T3 (pl) 2016-10-07 2021-10-18 Oric Pharmaceuticals, Inc. Inhibitor receptora glukokortykoidowego

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1918092A (en) * 1992-05-06 1993-11-29 Medical College Of Hampton Roads, The Minimizing progestin associated breakthrough bleeding
US5622943A (en) 1992-05-06 1997-04-22 The Medical College Of Hampton Roads Minimizing progestin associated breakthrough bleeding

Also Published As

Publication number Publication date
MX9603889A (es) 1997-04-30
FI963049L (fi) 1996-10-01
SK282570B6 (sk) 2002-10-08
ATE235907T1 (de) 2003-04-15
EP0806952B1 (de) 2003-04-02
PT806952E (pt) 2003-08-29
HUT75930A (en) 1997-05-28
ES2196063T3 (es) 2003-12-16
KR970704451A (ko) 1997-09-06
JPH10512889A (ja) 1998-12-08
US6451780B1 (en) 2002-09-17
EP0806952A1 (de) 1997-11-19
PL316533A1 (en) 1997-01-20
UA37259C2 (uk) 2001-05-15
WO1996023503A1 (de) 1996-08-08
AU2561195A (en) 1996-08-21
HU9602668D0 (en) 1996-11-28
DE59510626D1 (de) 2003-05-08
NZ287024A (en) 2001-03-30
SK121996A3 (en) 1997-05-07
HU226276B1 (en) 2008-07-28
NO964155L (no) 1996-10-01
DK0806952T3 (da) 2003-06-16
AU714959B2 (en) 2000-01-13
FI117850B (fi) 2007-03-30
FI963049A0 (fi) 1996-08-01
CA2186953A1 (en) 1996-08-08
KR100370908B1 (ko) 2003-04-10
CA2186953C (en) 2009-11-10

Similar Documents

Publication Publication Date Title
FI963049A0 (fi) Progesteroniantagonisteja lääkeaineiden valmistamiseksi, jotka on tarkoitettu kohdun toimintahäiriöistä johtuvien verenvuotojen hoitamiseksi
TR199901172T2 (xx) Yeni ikame edilmi� pirazol t�revleri.
DZ3402A1 (fr) Cyclopentanoindoles, compositions contenant ces composes et methodes de traitement
TR199901174T2 (xx) Yeni heterosiklilmetil-ikameli pirazol t�revleri.
ATE390917T1 (de) Prävention und behandlung von skeletterkrankungen mit ep2 subtyp selektiven prostaglandin e2 agonisten
SE0100568D0 (sv) Compounds
DZ3265A1 (fr) Derives de 4,5-diaryl-3(2h)-furanone comme inhibiteurs de cyclo-oxygenase-2
NO994850L (no) Farmakologiske midler
NO164656C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktivt 1-(4-amionfenyl)-4-methyl-7,8-methylendioxy-3,4-dihydro-5h-2,3-benzodiazepin.
EA199800692A1 (ru) Изолируемые смеси из семян eugenia jambolana lamarck, способы их получения, способ получения оксамата натрия, лекарственные средства для профилактики и лечения диабета и применение указанных смесей, их компонентов и оксамата натрия для получения этих лекарственных средств
SE0100566D0 (sv) Compounds
NO883122L (no) Fremgangsmaate for fremstilling av terapeutisk aktive arylamid-derivater.
ATE286883T1 (de) Isochinolin und chinazolinderivate mit kombinierter 5ht1a, 5ht1b und 5ht1d rezeptor aktivität
ES2191449T3 (es) Derivados de ciclopentabenzofurano y su uso.
PT684816E (pt) Composicoes antagonistas do receptor da 5-ht2 uteis no tratamento de doencas venosas
NO971869L (no) Konkurransedyktige progesteronantagonister for behovsorientert, kvinnelig fertillitetskontroll
TR200100637T2 (tr) Yeni doğal ürün türevleri
DE59809283D1 (de) Inhibitoren für den urokinaserezeptor
ES2188909T3 (es) Nuevos derivados de cis-3,4-cromano utiles para la prevencion o tratamiento de sindromes o enfermedades relacionados con el estrogeno. os
SE0101692D0 (sv) Compounds
IT1289154B1 (it) Derivati di isoflavone loro preparazione e loro impiego terapeutico
NO175746C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktivt 1-etyl-fenoksatiin-10,10-dioksyd
NO904470D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive benzodiazepinderivater.
TR200000916T2 (tr) İkameli piperidin türevleri.
NO903705D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive n,n-disubstituerte arylcykloalkylaminer.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application